TCM
RCUS icon

Teza Capital Management’s Arcus Biosciences RCUS Stock Holding History

Teza Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,198
Closed -$152K – 561
2024
Q4 		$152K Sell
10,198
-3,495
-26% -$57.1K 0.02% 448
2024
Q3 		$209K Sell
13,693
-10,012
-42% -$158K 0.02% 545
2024
Q2 		$361K Buy
+23,705
New +$383K 0.04% 415
2023
Q3 		– Sell
-10,157
Closed -$206K – 736
2023
Q2 		$206K Buy
+10,157
New +$193K 0.03% 505

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Teza Capital Management's RCUS Position: Q1 2025 in Review

Teza Capital Management sold out of Arcus Biosciences (RCUS) in Q1 2025, closing a stake of 10,198 shares — an estimated $152K sold.

Teza Capital Management first reported a position in RCUS in Q2 2023 and held it in 4 quarters. The position peaked at $361K in Q2 2024. 186 funds tracked by Wall St. Rank hold RCUS as of Q1 2025.

  • Teza Capital Management reported no remaining Arcus Biosciences position as of Q1 2025 after selling out during the quarter.
  • Teza Capital Management sold 10,198 Arcus Biosciences shares in Q1 2025, an estimated $152K.
  • Teza Capital Management first reported a position in Arcus Biosciences in Q2 2023 and held it in 4 quarters.
  • Teza Capital Management's Arcus Biosciences position peaked at $361K in Q2 2024.
  • 186 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2025.

Based on Teza Capital Management's 13F filing for Q1 2025, filed 15 May 2025.